Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey.
Sarlós P, Bikar A, Farkas N, Resál T, Szepes Z, Farkas K, Nagy F, Vincze Á, Miheller P, Molnár T. Sarlós P, et al. Among authors: szepes z. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):827-832. doi: 10.1080/14712598.2023.2211204. Epub 2023 May 9. Expert Opin Biol Ther. 2023. PMID: 37161387
Long-term outcomes after endoscopic removal of malignant colorectal polyps: Results from a 10-year cohort.
Fábián A, Bor R, Vasas B, Szűcs M, Tóth T, Bősze Z, Szántó KJ, Bacsur P, Bálint A, Farkas B, Farkas K, Milassin Á, Rutka M, Resál T, Molnár T, Szepes Z. Fábián A, et al. Among authors: szepes z. World J Gastrointest Endosc. 2024 Apr 16;16(4):193-205. doi: 10.4253/wjge.v16.i4.193. World J Gastrointest Endosc. 2024. PMID: 38680198 Free PMC article.
Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone.
Resál T, Mangó K, Bacsur P, Szántó K, Pigniczki D, Keresztes C, Rutka M, Bálint A, Milassin Á, Bor R, Fábián A, Szepes Z, Farkas K, Monostory K, Molnár T. Resál T, et al. Among authors: szepes z. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):517-524. doi: 10.1080/14740338.2023.2181336. Epub 2023 Feb 23. Expert Opin Drug Saf. 2023. PMID: 36811412
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study.
Bacsur P, Matuz M, Resál T, Miheller P, Szamosi T, Schäfer E, Sarlós P, Iliás Á, Szántó K, Rutka M, Bálint A, Milassin Á, Fábián A, Bor R, Szepes Z, Molnár T, Farkas K. Bacsur P, et al. Among authors: szepes z. Therap Adv Gastroenterol. 2022 Dec 26;15:17562848221144349. doi: 10.1177/17562848221144349. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36600684 Free PMC article.
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; I-CARE collaborator group. Amiot A, et al. J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091. J Crohns Colitis. 2023. PMID: 35767639 Free PMC article.
Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer.
Paszt A, Ottlakan A, Abraham S, Simonka Z, Vas M, Maraz A, Szepes Z, Tiszlavicz L, Nyari T, Olah J, Lazar G. Paszt A, et al. Among authors: szepes z. Pathol Oncol Res. 2022 Dec 8;28:1610722. doi: 10.3389/pore.2022.1610722. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36567978 Free PMC article.
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study.
Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi T, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T. Resál T, et al. Among authors: szepes z. Inflamm Bowel Dis. 2024 May 2;30(5):768-779. doi: 10.1093/ibd/izad135. Inflamm Bowel Dis. 2024. PMID: 37542737 Free PMC article.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
160 results